Altre lingue Seres Therapeutics, Inc.

Azioni

MCRB

US81750R1023

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
0,7295 ^USD	-4,01%		+16,29%	-47,89%

09/04	Seres Therapeutics annuncia il completamento dell'arruolamento dei pazienti per lo studio clinico SER-155 di Fase 1B Coorte 2 nel TCS allogenico	CI
06/03	SERES THERAPEUTICS, INC. : Oppenheimer rimane Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	09/04
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	09/04
Declaration of Voting Results by Seres Therapeutics	08/04
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	28/03
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	20/03
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19/03
Seres Therapeutics Files a Definitive Proxy Statement with Securities and Exchange Commission	05/03
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	05/03
North American Morning Briefing : S&P 500 Futures -2-	05/03
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024	28/02
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference	27/02
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz	26/02
Seres Therapeutics, Inc. Announces Chief Financial Officer Changes	26/02
Seres Therapeutics Appoints Marella Thorell as Executive Vice President	26/02
Kenneth Steiner Submits a Shareholder Proposal to Seres Therapeutics	23/02
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	18/01
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	17/01
SERES THERAPEUTICS ANNOUNCES VOWST COMMERCIAL LAUNCH UPDATE AND US FDA FAST TRACK DESIGNATION FOR SER-155	10/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Seres Therapeutics, Inc.

Azioni

MCRB

US81750R1023

Altre lingue

Filtri